“…Among EVALI patients, careful and comprehensive discharge planning ensuring clinical stability before discharge, follow-up optimally within 48 hours after hospital discharge, and enhanced efforts to coordinate care and address comorbidities might minimize risk for rehospitalizations or death after discharge (5). The latest national and state data from patient reports and product sample testing suggest tetrahydrocannabinol-containing e-cigarette, or vaping, products, particularly from informal sources such as friends, family members, or in-person or online dealers, are linked to most of the cases and play a major role in the outbreak (1,7,8). Thus, CDC and FDA recommend that persons not use tetrahydrocannabinol -containing e-cigarette, or vaping, products, particularly from informal sources.…”